Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25823443 | 0.89 | CACNA1B (0.48) | CACNA1BSMN1; SMN2KDM4EALDH1A1LMNA | |
| SCHEMBL25821996 | 0.88 | CACNA1B (0.47) | CACNA1BSMN1; SMN2KDM4EALDH1A1LMNA | |
| SCHEMBL2204508 | 0.87 | CACNA1B (0.43) | CACNA1BSMN1; SMN2KDM4EALDH1A1LMNA | |
| SCHEMBL2205412 | 0.86 | CACNA1B (0.47) | CACNA1BSMN1; SMN2KDM4EALDH1A1LMNA | |
| SCHEMBL19291558 | 0.86 | CACNA1B (0.47) | CACNA1BSMN1; SMN2KDM4EALDH1A1LMNA | |
| SCHEMBL29818806 | 0.86 | CACNA1B (0.47) | CACNA1BSMN1; SMN2KDM4EALDH1A1LMNA | |
| SCHEMBL27996046 | 0.86 | HPGD (0.51) | SMN1; SMN2KDM4EALDH1A1LMNAHPGD | |
| SCHEMBL4568896 | 0.85 | CACNA1B (0.54) | CACNA1BSMN1; SMN2KDM4EALDH1A1LMNA | |
| SCHEMBL3968993 | 0.82 | KDM4E (0.43) | SMN1; SMN2KDM4EALDH1A1LMNAHPGD | |
| SCHEMBL27996248 | 0.79 | CYP2D6 (0.57) | HPGDCYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122938-A1 | Alkoxy Compounds for Disease Treatment | ACUCELA INC. (US) | 2012-05-17 | — | — | US | disclosed |
| EP-2091955-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | Acucela, Inc. (US) | 2009-08-26 | — | — | EP | disclosed |
| WO-2009045479-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122938-A1 | Alkoxy Compounds for Disease Treatment | ALDH1A2, CLN6, AGER | CACNA1B 4265/4885SMN1; SMN2 42/4885KDM4E 2349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.